[ad_1]
Remote guest in the UK show Good morning Great Britain, a vaccine tester designed by Moderna has provided some information on the clinical trials of the American laboratory.
It was among the first to be inoculated with the candidate vaccine designed by the Moderna laboratory. Neal Browning, an American volunteer from Bothell (Washington), appeared in videoconference on the British program Good morning Great Britain, broadcast on the ITV channel, in order to discuss the clinical trials of the remedy whose effectiveness would be greater than 94%.
“Minimal” risks
Browning, who was the second person to receive the vaccine in tests conducted by the American laboratory, believes in particular that the risks of such tests are “minimal” compared to the positive impact that the discovery of a cure could have. All over the world.
“I’ve done the research. They’ve produced a lot of material explaining how it works, what it does. The risks seem small compared to the benefits the world could get.”
A “very slightly painful” arm
“Since I was in the first trial, they gave us the dose and let us stay in the clinic for about an hour to make sure there were no adverse reactions, as it wasn’t” it had never been tested on animals before, let alone on human beings”, says the volunteer.
As for the side effects after the injection, explain in detail: “the second injection was four weeks later. Both times I had no problems except waking up with a sore arm – very slightly sore – the next morning. Just like a regular flu shot“.
“No chance to catch Covid-19”
Finally, Neal Browning reassured those who would be concerned that a possible vaccine could transmit the virus: “there is no possibility of contracting Covid-19 because there is no part of the virus in this vaccine“.
Following the announcement of the partial success of its clinical trials, Moderna is now considering applying for an authorization to start using its vaccine. But the latter is not expected to hit the market until next spring, like many other vaccines.
Source link